Prospect for Application of PARP Inhibitor in Patients with HER2 Negative Breast Cancer

Human epidermal growth factor receptor (HER2) negative metastatic breast cancer (BC) accounts for 73% of BC. The molecular analysis of this disease is essential for potential options for targeted therapy. Several promising clinical strategies are being evaluated which includes endocrine therapy, mod...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Int J Biol Sci
Main Authors: Shao, Nan, Shi, Yawei, Yu, Liang, Ye, Runyi, Shan, Zhen, Zhang, Zhanqiang, Zhang, Yunjian, Lin, Ying
Format: Artigo
Jezik:Inglês
Izdano: Ivyspring International Publisher 2019
Teme:
Review
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6535782/
https://ncbi.nlm.nih.gov/pubmed/31182917
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/ijbs.30721
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki